|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:ATCCode
|
C10AX16
|
|
gptkbp:CASNumber
|
1639324-58-2
|
|
gptkbp:chemicalFormula
|
C520H642N176O164P43S6
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:developer
|
gptkb:Alnylam_Pharmaceuticals
|
|
gptkbp:drugClass
|
gptkb:small_interfering_RNA_(siRNA)
|
|
gptkbp:EMA_approval_date
|
2020
|
|
gptkbp:FDAApproved
|
2021
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:frequency
|
every 6 months after initial doses
|
|
gptkbp:genericName
|
inclisiran
|
|
gptkbp:halfLife
|
~9 months
|
|
gptkbp:indication
|
gptkb:familial_hypercholesterolemia
mixed dyslipidemia
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketer
|
gptkb:Novartis
|
|
gptkbp:mechanismOfAction
|
PCSK9 inhibitor
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
bronchitis
urinary tract infection
injection site reaction
arthralgia
|
|
gptkbp:target
|
gptkb:PCSK9_mRNA
|
|
gptkbp:usedFor
|
lowering LDL cholesterol
|
|
gptkbp:bfsParent
|
gptkb:PCSK9_inhibitors
gptkb:NOVN
gptkb:Inclisiran
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Leqvio
|